Crestor Cost in Delaware 2026: Rosuvastatin Prices, Insurance, and Savings Options

What Does Crestor Actually Cost in Delaware in 2026?

The brand-name Crestor list price sits near $290 per month in 2026, but that figure is almost irrelevant for most Delaware residents. Generic rosuvastatin, available from multiple manufacturers since patent expiry, averages roughly $15 per month at Delaware retail pharmacies on a cash-pay basis. Patients with insurance or Medicaid typically pay far less, and those who qualify for compounded formulations through a licensed 503A pharmacy may pay nothing at all.

Brand vs. Generic Price Gap

AstraZeneca's wholesale acquisition cost for Crestor 20 mg (30 tablets) is approximately $290 in 2026. That gap between $290 and $15 is not accidental. Generic entry drove rosuvastatin prices down sharply after the first generics launched in 2016 [1]. The FDA tracks generic approvals through its Orange Book, which currently lists more than a dozen approved rosuvastatin manufacturers [2].

What Determines Your Out-of-Pocket Cost

Three variables set what you actually pay: insurance tier placement, pharmacy choice, and whether you qualify for manufacturer or assistance programs. A Delaware resident with a commercial plan that places generic rosuvastatin on Tier 1 might pay a $5 to $10 copay. Without insurance, GoodRx-type discount codes at pharmacies such as Walmart or Costco in Wilmington or Dover routinely bring 10 mg or 20 mg rosuvastatin below $12 for a 30-day supply.

Does Delaware Medicaid Cover Crestor?

Delaware Medicaid (administered through Diamond State Health Plan managed care organizations) covers rosuvastatin with a prior authorization requirement [3]. The PA process exists because Delaware Medicaid's preferred drug list favors lower-cost statins, particularly simvastatin and atorvastatin, as first-line agents. Prescribers documenting a clinical reason for rosuvastatin specifically, such as muscle intolerance to other statins or a specific LDL-C target not met on alternatives, generally obtain approval.

Prior Authorization: What Clinicians Need to Document

To support a PA for rosuvastatin under Delaware Medicaid, the prescribing clinician typically must show one or more of the following: documented adverse effect or contraindication to at least one preferred statin, established atherosclerotic cardiovascular disease (ASCVD) requiring high-intensity therapy, or failure to achieve guideline-based LDL-C goals on preferred agents [4].

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states: "High-intensity statin therapy should be initiated or continued as first-line therapy in patients 75 years of age or younger with clinical ASCVD" [5]. Rosuvastatin 20 mg and 40 mg are explicitly listed as high-intensity options in that guideline table, which strengthens PA documentation.

Delaware Medicaid Managed Care Plans

Delaware Medicaid operates through two primary MCOs: Highmark BCBS Delaware and Molina Healthcare of Delaware. Each MCO maintains its own formulary, but both follow the state's preferred drug list as a foundation. Contacting the MCO's pharmacy helpline with the prescribing physician's clinical notes typically resolves PA requests within 72 hours for urgent cardiovascular indications.

Is Compounded Rosuvastatin Legal in Delaware?

Yes. Compounded rosuvastatin is legal in Delaware when prepared by a licensed 503A pharmacy operating under valid state and federal rules [6]. A 503A pharmacy compounds medications for individual patients in response to a valid prescription. Delaware's Board of Pharmacy licenses and inspects these facilities, and the FDA oversees compliance with the Federal Food, Drug, and Cosmetic Act's compounding provisions [7].

How 503A Compounding Works

A 503A pharmacy receives a patient-specific prescription from a licensed prescriber, then compounds the medication using USP-grade active pharmaceutical ingredients. The final product is dispensed directly to that named patient. Compounded rosuvastatin is not interchangeable with FDA-approved tablets, and the FDA does not evaluate the safety or efficacy of compounded versions. Patients should use only pharmacies that are state-licensed in Delaware and in good standing with the NABP.

Why the Cost Can Reach $0

Some telehealth platforms that operate in Delaware bundle compounded medications, including rosuvastatin, into membership or subscription fees. In those models, the medication itself carries no additional per-fill charge, making the effective out-of-pocket cost $0 per month. This model is distinct from insurance billing; it relies on direct-pay agreements between the platform and the 503A pharmacy. Delaware law does not prohibit this arrangement provided a valid prescriber-patient relationship and prescription exist [8].

Legal Boundaries to Understand

Compounded rosuvastatin cannot be mass-produced and sold without patient-specific prescriptions under 503A rules. It cannot be advertised as equivalent to FDA-approved rosuvastatin. Delaware prescribers have a legal and ethical obligation to ensure the compounding pharmacy they direct patients to is licensed and inspected. The FDA's guidance on compounding from bulk drug substances sets the outer limits [7].

Rosuvastatin's Clinical Evidence: Why Physicians Prescribe It

Rosuvastatin is not prescribed merely because it is cheap or convenient. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced the incidence of major cardiovascular events by 44% versus placebo in patients with elevated high-sensitivity CRP but LDL-C below 130 mg/dL, with a hazard ratio of 0.56 (95% CI 0.46 to 0.69, P<0.001) [9]. That trial enrolled adults with no prior cardiovascular disease, expanding rosuvastatin's clinical footprint beyond secondary prevention.

LDL-C Lowering Potency

Rosuvastatin is the most potent statin by milligram-for-milligram LDL-C reduction. At 10 mg, it produces approximately 46% LDL-C lowering; at 20 mg, roughly 52%; at 40 mg, around 55% [10]. Atorvastatin 80 mg (the other commonly used high-intensity statin) produces comparable LDL-C reductions to rosuvastatin 20 to 40 mg, but some patients tolerate one better than the other.

Safety Profile Relevant to Delaware Prescribers

The FDA label for rosuvastatin notes myopathy and rhabdomyolysis as rare but serious risks, with incidence rates below 0.1% in clinical trials [11]. Dose-dependent increases in HbA1c have been observed across statin class, an effect documented in the JUPITER trial data. Asian patients metabolize rosuvastatin differently due to OATP1B1 transporter differences; the FDA label recommends starting at 5 mg in Asian patients rather than 10 mg [11].

FDA Approval and Labeled Indications

The FDA approved rosuvastatin (brand name Crestor) in 2003 for multiple indications: primary hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and slowing of atherosclerosis progression [11]. The labeled dosing range is 5 mg to 40 mg once daily. The 40 mg dose is restricted to patients who have not achieved their LDL-C goal on 20 mg.

Which Delaware Insurance Plans Cover Rosuvastatin?

Most commercial insurance plans operating in Delaware cover generic rosuvastatin. The question is which tier it lands on, because tier placement determines the copay.

Tier Placement by Plan Type

Commercial plans in Delaware sold through the ACA marketplace (healthcare.gov) generally place generic rosuvastatin on Tier 1 or Tier 2, translating to $0 to $20 copays in 2026. Plans that place brand Crestor on formulary at all typically put it on Tier 3 or Tier 4, with cost-sharing ranging from $45 to over $100 per month. Employer-sponsored plans vary widely, but large Delaware employers such as state government and healthcare systems typically cover generic rosuvastatin at Tier 1 [12].

Medicare Part D in Delaware

Medicare Part D covers rosuvastatin on almost every standalone Part D plan and Medicare Advantage plan available in Delaware. Under the Inflation Reduction Act's drug pricing provisions, starting in 2025 Part D out-of-pocket costs for covered drugs are capped; the $2,000 annual out-of-pocket cap may bring rosuvastatin costs to $0 for many Part D enrollees who also take other medications [13]. Delaware residents can compare specific Part D plans at CMS's Medicare Plan Finder tool.

Highmark BCBS Delaware and Aetna Specifics

Highmark BCBS Delaware places generic rosuvastatin on Tier 1 of its standard formulary for most commercial products, with a $0 to $5 copay at preferred pharmacies. Aetna plans sold in Delaware similarly list generic rosuvastatin at Tier 1 or Tier 2. United Healthcare and Cigna plans in Delaware follow comparable structures. Patients should verify their specific plan's formulary at the insurer's website or by calling the member services number on their card.

The Cheapest Ways to Get Rosuvastatin in Delaware

For Delaware residents without insurance or with high deductibles, several paths can bring rosuvastatin costs below $15 per month or to $0.

GoodRx and Discount Card Programs

GoodRx, RxSaver, and similar programs negotiate discounted cash prices at retail pharmacies. In Wilmington, Newark, and Dover, GoodRx prices for generic rosuvastatin 10 mg (30 tablets) range from approximately $8 to $14 in early 2026. These programs are not insurance; they are discount arrangements between the program and the pharmacy. They cannot be combined with insurance billing at most pharmacies.

AstraZeneca Patient Assistance and Savings Cards

AstraZeneca offers the AZ&Me Prescription Savings program for brand Crestor. Eligible patients with commercial insurance may pay as little as $0 per month for brand Crestor using the savings card, subject to eligibility criteria including income limits and insurance status [14]. Patients without insurance who meet income thresholds may qualify for the full patient assistance program, which provides brand Crestor at no cost. Applications are submitted through AstraZeneca's patient assistance portal.

$4 Generics and Warehouse Pharmacies

Walmart's $4 generic program includes rosuvastatin at select doses. Costco in Delaware consistently offers low-cost generics without requiring a Costco membership for pharmacy services. Sam's Club and Kroger (in regions where available near Delaware) participate in similar low-cost generic programs. Calling the pharmacy directly before visiting remains the fastest way to confirm current cash pricing.

Telehealth Platforms Operating in Delaware

Several telehealth platforms prescribe rosuvastatin to Delaware residents via synchronous video visits or, where Delaware law permits, asynchronous questionnaire-based consultations. Some of these platforms include generic rosuvastatin dispensed by mail in a flat monthly membership fee, which may effectively reduce medication cost to $0 beyond the platform fee itself [15]. Delaware does not restrict telehealth prescribing of non-controlled substances such as rosuvastatin, making this a legal and accessible option.

How to Use the AstraZeneca Savings Card in Delaware

The AstraZeneca savings card for Crestor (brand) works at participating Delaware pharmacies through a simple three-step process: obtain the card or digital code from the AZ&Me website, present it to the pharmacist alongside your prescription, and the card covers the portion of the cost above your plan copay up to the program maximum [14].

Eligibility Criteria

The savings card is available to patients with commercial insurance who are not enrolled in a federal or state government insurance program (including Medicare, Medicaid, or TRICARE). Delaware Medicaid enrollees are not eligible. There is no income requirement for the commercial savings card, but the full patient assistance program (for uninsured patients) does require income documentation.

What the Card Does Not Cover

The card does not reduce deductible spending in plans where the pharmacy benefit requires the deductible to be met first. Patients in high-deductible health plans who have not yet met their deductible will find the card less effective until their deductible clears. In those cases, GoodRx pricing or the telehealth platform model may produce lower actual out-of-pocket costs.

ACC/AHA Guidelines and Delaware Prescribing Practice

Delaware prescribers largely follow the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol for statin selection and intensity [5]. That guideline introduced the concept of risk-enhancing factors and coronary artery calcium (CAC) scoring to guide initiation decisions for patients in the borderline (7.5% to 20%) 10-year ASCVD risk range. Rosuvastatin specifically appears in the guideline's high-intensity statin table alongside atorvastatin 40 to 80 mg [5].

The guideline states: "Clinicians and patients should engage in a risk discussion that considers risk-enhancing factors before initiating statin therapy in primary prevention patients" [5]. This language means Delaware clinicians are expected to individualize statin selection rather than default to any single agent.

A 2021 systematic review in JAMA confirmed that high-intensity statin therapy reduces major vascular events with an absolute risk reduction proportional to baseline cardiovascular risk, reinforcing guideline recommendations for rosuvastatin as a first-line high-intensity option [16].

Rosuvastatin Dosing in Delaware Clinical Practice

Delaware prescribers use rosuvastatin across its full 5 mg to 40 mg labeled dosing range, calibrated by patient LDL-C goals, risk category, and tolerability [11].

Standard Starting Doses

For primary prevention in low-to-moderate risk adults, 5 mg to 10 mg daily is a common starting point. For high-intensity therapy in ASCVD patients, 20 mg to 40 mg is standard per ACC/AHA guidance [5]. The 40 mg dose should be reserved for patients who do not achieve adequate LDL-C lowering on 20 mg. Dose titration typically follows a 4 to 12-week lipid panel recheck [10].

Drug Interactions Relevant in Delaware Practice

Cyclosporine raises rosuvastatin exposure substantially; the FDA label caps the rosuvastatin dose at 5 mg in patients on cyclosporine [11]. Antacids containing aluminum and magnesium reduce rosuvastatin absorption when taken simultaneously. Warfarin interaction monitoring is warranted, as rosuvastatin modestly potentiates warfarin's anticoagulant effect. Delaware pharmacies with integrated electronic prescription records generally flag these interactions automatically.

Monitoring Parameters

A fasting lipid panel at 4 to 12 weeks after initiation or dose change confirms treatment response. Creatine kinase (CK) measurement is not routinely recommended unless the patient reports muscle symptoms. Liver enzyme monitoring is no longer routine per FDA label revision, but baseline ALT is reasonable before starting therapy in patients with known liver disease [11].

Comparing Rosuvastatin to Other Statins Available in Delaware

Delaware residents often ask whether rosuvastatin is the right statin choice compared to atorvastatin (the most prescribed statin in the US), simvastatin, or pravastatin.

Rosuvastatin vs. Atorvastatin

Both are high-intensity options at their upper doses. Atorvastatin 80 mg produces LDL-C reductions of approximately 50 to 60%, comparable to rosuvastatin 20 to 40 mg [10]. Atorvastatin is generally priced similarly or slightly lower at Delaware pharmacies. The SATURN trial (N=1,385) compared rosuvastatin 40 mg and atorvastatin 80 mg head-to-head for atherosclerosis regression and found rosuvastatin produced slightly greater regression of coronary atherosclerosis volume, though both drugs produced clinically meaningful regression [17].

Rosuvastatin vs. Simvastatin

Simvastatin is a lower-intensity statin at standard doses (20 to 40 mg). The FDA issued a label change in 2011 restricting simvastatin 80 mg due to myopathy risk, making it unavailable as a high-intensity option for new patients [18]. Delaware Medicaid favors simvastatin as a preferred agent for low-to-moderate intensity needs, but patients requiring high-intensity therapy have a clear clinical basis for rosuvastatin.